MHRA (UK)
OTHER
Class 4 Medicines Defect Notification: Milpharm Limited, Loperamide hydrochloride 2 mg Orodispersible Tablets, EL(26)A/23
Published: 5/11/2026Detected: 5/11/2026
Summary preview
Class 4 defect notification addressed to Milpharm Limited highlights a discrepancy in the previously approved Patient Information Leaflet (PIL) for loperamide hydrochloride 2 mg orodispersible tablets.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountgastroenterology
labeling
safety
quality
#MHRA
#Class 4
#defect notification
#patient information leaflet
#PIL
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/4811/12/2026
- Field Safety Notices from 02 to 06 November2026.11/10/2026
- Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/4611/5/2026
- Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/4711/5/2026
- Field Safety Notices: 26 to 30 October 202611/4/2026